Allergan has bought the privately-held biotech Bonti, which has been developing a fast-acting, short duration replacement alternative to Botox ahead of potentially che
Pfizer is calling for the FDA to issue guidance on what originator companies can say about cheaper biosimilars of their products, and prevent them using “scare tactics” to keep doctors pres
AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European patent presents healthcare providers with a major cost-saving opportunity for a biosi
The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic drugs, which are considered to be “equally effective alternatives
European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first oncology biosimilar to receive approval in the EU.